IFF (IFF) Sells Pharma Solutions Business to Roquette for Up to $2.85B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
International Flavors & Fragrances (IFF) PT Raised to $85 at BofA Securities
March 20, 2024 2:10 PM EDTBofA Securities analyst Matthew DeYoe raised the price target on International Flavors & Fragrances (NYSE: IFF) to $85.00 (from $83.00) while maintaining a Neutral rating.
The analyst comments "Yesterday, IFF announced an agreement to sell its Pharma Solutions business to Roquette for $2.85bn. The transaction reflects a... More
International Flavors & Fragrances (IFF) PT Raised to $100 at Deutsche Bank
March 20, 2024 5:19 AM EDTDeutsche Bank analyst David Begleiter raised the price target on International Flavors & Fragrances (NYSE: IFF) to $100.00 (from $90.00) while maintaining a Buy rating.
The analyst comments "With the sale of Pharma Solutions, IFF has taken a major step in reducing its leverage below 3x and thus removing the leverage overhang on the shares that has existed since the... More
International Flavors & Fragrances (IFF) PT Raised to $85 at Stifel
March 19, 2024 10:24 AM EDTStifel analyst Mark Astachan raised the price target on International Flavors & Fragrances (NYSE: IFF) to $85.00 (from $80.00) while maintaining a Hold rating after selling its Pharma business for up to $2.85 billion.
The analyst commented, "IFF announced the sale of its Pharma business for up to $2.85bn,... More
